Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients

Guo, Fang; Gong, Hai Feng; Zhao, Huanhuan; Chen, Jing; Zhang, Yiming; Zhang, Lihua; Shi, Xin; Zhang, Aifeng; Jin, Hui; Zhang, Jianqiong; He, Yao

doi:10.1038/s41598-018-24306-1

Cited by 79 publications

(91 citation statements)

References 36 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with the previous studies (Table 5 ), the mutation rate of KRAS in CRC reported in our study was consistent with that reported by Douillard et al ( 6 ) and Gao et al ( 25 ), who also focused on exons 2, codon 12/13. Guo et al ( 13 ) believed that the mutation rate of KRAS was as high as 52.7%. This conclusion may be because they included more genetic loci into the study (exons 2/3/4, codons 12/13/59/61/117/146/147).…”

Section: Discussionmentioning

confidence: 99%

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

et al. 2018

View full text Add to dashboard Cite

KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tumor-driven genes. Patients with KRAS/NRAS/BRAF mutations are resistant to anti-EGFR monoclonal antibody therapy. The main purpose of this study is to investigate the mutation status and distribution of KRAS/NRAS/BRAF in Chinese colorectal and gastric cancers, and to explore the histopathological changes and related immunohistochemical marker changes caused by these mutations. The mutation status of KRAS (exons 2, codon 12/13), NRAS (exons 2/3/4, codon 12/13/59/61/117/146) and BRAF (exons 15, codon 600) were detected by amplification refractory mutation system polymerase chain reaction (ARMS-PCR) in 86 colon cancer, 140 rectal cancer and 34 gastric cancer tissues. Then, the frequencies and distribution of KRAS/NRAS/BRAF mutations were described in detail. Furthermore, the relationship between KRAS/NRAS/BRAF mutations and the features of histopathological and related immunohistochemical markers were analyzed. The results showed that KRAS/NRAS/BRAF mutation rates in colon cancer were 44.2, 1.2, and 3.5%; in rectal cancer were 37.1, 4.3, and 0.7%; in gastric cancer were none, none and 2.9%. The mutation rate of KRAS in female (48.8%) is significantly higher than that of male (27.8%), and the mutation rate increased with the higher degree of differentiation. Additionally, the mutation rate of BRAF detected by ARMS-PCR (1.77%) was significantly lower than that by immunohistochemistry (4.11%). It also showed that the KRAS/NRAS/BRAF mutation status had a certain relationship with the expression of some immunohistochemical markers. This study provides more data support for clinical research on KRAS/NRAS/BRAF mutation in CRCs or gastric cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It showed that mutations in KRAS/NRAS, BRAF and PIK3CA genes were not associated with pathological status of colorectal cancer. There are different domestic and foreign studies on the relationship between KRAS/NRAS, BRAF and PIK3CA gene mutation status and pathological characteristics in colorectal cancer, which may be related to the detection method, sample size and regional differences [33][34][35].…”

Section: Discussionmentioning

confidence: 99%

Clinical Diagnostic Value for Colorectal cancer Based on Serum CEA, CA24-2 and CA19-9

Rao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To explore the clinical value of a combined detection of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) for colorectal cancer (CRC).Methods The levels of serum tumor markers (CEA, CA24-2 and CA19-9) and clinicopathologic features in patients with colorectal cancer in Meizhou People's Hospital were evaluated. In addition, KRAS/NRAS, PIK3CA and BRAF mutations were detected in some patients with colorectal cancer.Results A total of 2,281 patients (1,420 males and 861 females) were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. The levels of CEA, CA24-2 and CA19-9 in colorectal cancer group was significantly higher than control group. The sensitivities of three individual markers were lower than 30%, which individual sensitivity of the tumor markers sorted in descending order were CEA> CA19-9> CA24-2. The specificities of three individual markers were more than 92%, and the specificity sorted in descending order were CA24-2> CA19-9> CEA. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 -0.28CEA -0.11 CA242 + 0.001 CA199)/ (1+ Exp (-5.47 -0.28CEA -0.11 CA242 + 0.001 CA199)). There were no significant differences in age, gender, histology type, differentiation, depth of invasion and TNM stage between mutations in KRAS/NRAS , BRAF and PIK3CA genes or not, respectively.Conclusions Serum CEA, ca24-2, and ca19-9 are valuable noninvasive indicators for the detection and screening of patients with early colon cancer. We need to look for other, more sensitive tumor markers.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Diagnostic Value for Colorectal Cancer Based on Serum CEA, CA24-2 and CA19-9

Rao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background To explore the clinical value of a combined detection of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) for colorectal cancer (CRC). Methods The levels of serum tumor markers (CEA, CA24-2 and CA19-9) and clinical characteristics in patients with colorectal cancer were evaluated. In addition, KRAS/NRAS/PIK3CA/BRAF mutations were detected in some patients with colorectal cancer. Results A total of 2,281 patients were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. The levels of CEA, CA24-2 and CA19-9 in colorectal cancer group was significantly higher than control group. The sensitivities of three individual markers were lower than 30%, which individual sensitivity of the tumor markers sorted in descending order was CEA>CA19-9>CA24-2. The specificities of three individual markers were more than 92%, and the specificity sorted in descending order was CA24-2>CA19-9>CEA. The combination of CEA+CA19-9+CA24-2 ranked the highest in sensitivity index and specificity index for colorectal cancer diagnosis. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 - 0.28CEA - 0.11 CA242 + 0.001 CA199)/ (1+ Exp (-5.47 - 0.28CEA - 0.11 CA242 + 0.001 CA199)). There were no significant differences in age, gender, histology type, differentiation, depth of invasion and TNM stage between mutations in KRAS/NRAS, BRAF and PIK3CA genes or not, respectively. Conclusions Serum CEA, CA24-2, and CA19-9 are valuable noninvasive indicators for prediction the risk of colorectal cancer. We need to look for other, more sensitive tumor markers.

show abstract

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients

Cited by 79 publications

References 36 publications

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

Clinical Diagnostic Value for Colorectal cancer Based on Serum CEA, CA24-2 and CA19-9

Clinical Diagnostic Value for Colorectal Cancer Based on Serum CEA, CA24-2 and CA19-9

Contact Info

Product

Resources

About